A Novel Approach to Treat Parkinson’s Disease

This video is based on a news article and its source material on a novel treatment for Parkinson’s Disease. We begin by covering the basis of what Parkinson’s Disease is and what its’ current treatment options are. We then discuss how current treatment options often result in adverse health effects. The toxins that cause Parkinson’s arise from excessive conversion of the amino acid tryptophan. As such, researchers at the pharmaceutical company NTRC in the Dutch city of Oss, in the Netherlands, have developed a substance called NTRC3531-0 that inhibits the production of these toxic by-products. By inhibiting the production of these toxic by-products, dopamine production is corrected, thereby reducing the symptoms that come with Parkinson’s disease. The results seem promising, and with more research, this treatment plan can be implemented for other diseases as well. This drug is not yet available for use, and researchers are continuing to assess its efficacy. Therefore, this video is meant to provide general information, and it does not act as a substitute for medical advice. Please consult your health care provider for more information.

This video was made by McMaster students Muntaha Ahmed, Stephanie Amoah, William Douglas, Youssef El-Sayes in collaboration with the McMaster Demystifying Medicine Program

Copyright McMaster University 2021.


Chen, Y. S., Hong, Z. X., Lin, S. Z., & Harn, H. J. (2020). Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies. International journal of molecular sciences, 21(9), 3063. https://doi.org/10.3390/ijms21093063

Christensen, Monika & Fadnes, Dag & Røst, Therese & Pedersen, Eva & Andersen, John Roger & Våge, Villy & Ulvik, Arve & Midttun, Øivind & Ueland, Per & Nygård, Ottar & Mellgren, Gunnar. (2018). Inflammatory markers, the tryptophan-kynurenine pathway, and Vitamin B status after bariatric surgery. PLOS ONE. 13. e0192169. 10.1371/journal.pone.0192169.

Cornelissen, A. (2021, February 21). New medicine to treat Parkinson's disease one step closer. Retrieved from https://innovationorigins.com/new-medicine-to-treat-parkinsons-disease-one-step-closer

National Institute on Aging. (2017). Parkinson's Disease. Retrieved from https://www.nia.nih.gov/health/parkinsons-disease

Perez-Pardo, P., Grobben, Y., Willemsen-Seegers, N., Hartog, M., Tutone, M., Muller, M., . . . Kraneveld, A. D. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. The Febs Journal. doi:10.1111/febs.15721

Saint-Cyr, J. A., Taylor, A. E., & Lang, A. E. (1993). Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology, 43(12, Suppl 6), S47–S52.

Ye, Z., Yue, L., Shi, J., Shao, M., & Wu, T. (2019). Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications. Journal of Cancer, 10(12), 2771–2782. https://doi.org/10.7150/jca.31727

Be the first to comment